# Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

> **NCT03360682** · PHASE4 · COMPLETED · sponsor: **Fundacion Clinic per a la Recerca Biomédica** · enrollment: 19 (actual)

## Conditions studied

- HIV-1-infection
- Solid Organ Transplant

## Interventions

- **DRUG:** Lamivudine 300 MG
- **DRUG:** Abacavir 600 MG
- **DRUG:** Dolutegravir 50 mg
- **DRUG:** Tenofovir Disoproxil 245Mg Tablet
- **DRUG:** Emtricitabine 200 MG

## Key facts

- **NCT ID:** NCT03360682
- **Lead sponsor:** Fundacion Clinic per a la Recerca Biomédica
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-13
- **Primary completion:** 2020-05-21
- **Final completion:** 2020-05-21
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03360682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03360682, "Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03360682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*